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1494Background: The Biventricular Pacing After Cardiac Surgery trial investigates hemodynamics of temporary
pacing in selected patients at risk of left ventricular dysfunction. This trial demonstrates improved
hemodynamics during optimized biventricular pacing compared with atrial pacing at the same heart rate 1
and 2 hours after bypass and reduced vasoactive-inotropic score over the first 4 hours after bypass. However,
this advantage of biventricular versus atrial pacing disappears 12 to 24 hours later. We hypothesized that changes
in intrinsic heart rate can explain variable effects of atrial pacing in this setting.
Methods: Heart rate, mean arterial pressure, cardiac output, and medications depressing heart rate were
analyzed in patients randomized to continuous biventricular pacing (n ¼ 16) or standard of care (n ¼ 18).
Results:During 30-second testing periods without pacing, intrinsic heart rate was lower in the paced group 12 to
24 hours after bypass (76.5  17.5 vs 91.7  13.0 beats per minute; P ¼ .040) but not 1 or 2 hours after bypass.
Cardiac output (4.4  1.2 vs 3.6  1.9 L/min; P ¼ .054) and stroke volume (53  2 vs 42  2 mL; P ¼ .051)
increased overnight in the paced group. Vasoactive medication doses were not different between groups,
whereas dexmedetomidine administration was prolonged over postoperative hours 12 to 24 in the paced group
(793  528 vs 478  295 minutes; P ¼ .013).
Conclusions: These observations suggest that hemodynamic benefits of biventricular pacing 12 to 24 hours after
cardiopulmonary bypass lead to withdrawal of sympathetic drive and decreased intrinsic heart rate. Depression
of intrinsic rate increases the apparent benefit of atrial pacing in the chronically paced group but not in the
control group. Additional study is needed to define clinical benefits of these effects. (J Thorac Cardiovasc
Surg 2013;146:1494-500)Biventricular pacing (BiVP) is beneficial for patients with
heart failure characterized by ventricular dyssynchrony.1
BiVP can induce resynchronization, with function
optimized by adjusting the length of both atrioventricular
delay (AVD) and interventricular delay (VVD). BiVP
reduces morbidity and mortality and improves quality of
life and walking ability for patients with mild to severe heart
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The Journal of Thoracic and Cardiovascular Surgreater than 120 milliseconds and a left ventricular
ejection fraction (LVEF) of 35% or less.2-5 In addition,
BiVP, with or without an intracardiac defibrillator, can
reduce mortality and hospitalizations after implantation.3,6
Mechanistically, BiVP has improved LVEF and reversed
left ventricular (LV) remodeling characteristic of
advanced heart failure.5,7 More important, BiVP can
increase contractility without increasing myocardial
oxygen demand.8
BiVP may be beneficial for patients after open heart
surgery (OHS). Previous studies that investigated
temporary BiVP after OHS have used a primary eligibility
criterion of low preoperative LVEF, which can indepen-
dently predict risk of acute heart failure after OHS.9 These
studies have shown mixed results but suggest that BiVP is
most effective immediately after cardiopulmonary bypass
(CPB).10-13 Complicating these results is that up to 30%
of patients do not respond to permanent BiVP.2,14
Optimization of permanent BiVP pacing settings can
decrease this nonresponse rate,15,16 but the optimal
settings for temporary BiVP after OHS are unknown.
The Biventricular Pacing after Cardiac Surgery
(BiPACS) trial is a randomized, controlled study of tempo-
rary, optimized BiVP for patients undergoing OHS.gery c December 2013
Abbreviations and Acronyms
AAI ¼ atrial pacing
AVD ¼ atrioventricular delay
BiPACS ¼ Biventricular Pacing after Cardiac
Surgery
BiVP ¼ biventricular pacing
bpm ¼ beats per minute
CO ¼ cardiac output
CPB ¼ cardiopulmonary bypass
ICU ¼ intensive care unit
LVEF ¼ left ventricular ejection fraction
MAP ¼ mean arterial pressure
OHS ¼ open heart surgery
QRSd ¼ QRS duration
SOC ¼ standard of care
VIS ¼ vasoactive-inotrope score
VVD ¼ interventricular delay
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MEnrollemnt criteria are described in Methods. The primary
end point for this study is cardiac index, measured by ther-
modilution in the intensive care unit (ICU). In addition, the
BiPACS trial tests optimization of BiVP for all enrolled pa-
tients at 3 time points: immediately after CPB (phase I), af-
ter chest closure (phase II), and 12 to 24 hours
postoperatively (phase III). At phase I in the BiPACS trial,
optimized BiVP increased cardiac output (CO) by 13%
compared with no pacing, whereas atrial pacing (AAI) at
the same heart rate provided no benefit.17 Interestingly, in
phase II, the effect of AAI was intermediate between no
pacing and optimized BiVP18; and in phase III, the benefit
of AAI was indistinguishable from BiVP.18 These data indi-
cate that BiVP increases stroke volume immediately after
CPB (phase I), whereas the benefit of BiVP and AAI in
the ICU (phase III) is primarily due to an increase in heart
rate.
Atrial pacing is, thus, increasingly effective from phase
I to phase III, but the mechanism for this trend is unde-
fined. We hypothesized that this increasing AAI efficacy
might be related to changes in intrinsic heart rate over
time after CPB. The pacing rate in AAI and BiVP modes
was 90 beats per minute (bpm) or 10 bpm higher than the
patient’s intrinsic heart rate if the intrinsic rate exceeded
90 bpm. Thus, a decrease in intrinsic heart rate could
augment the percentage increase in heart rate during
AAI pacing, in turn increasing the fractional change in
cardiac output.
This substudy analyzes changes in intrinsic heart rate
and related variables in phases I, II, and III of the BiPACS
trial. Because enrollment in the trial is complete, we are
also able to compare these variables across randomization
groups.The Journal of Thoracic and CarMETHODS
BiPACS Study Population
The BiPACS protocol is approved by the Columbia University Med-
ical Center Institutional Review Board and supported by the National
Institutes of Health under an investigational device exception from
the Food and Drug Administration (No. G050189). The protocol has
been described in detail previously.17 Adult patients undergoing elec-
tive surgery on CPB are screened for inclusion in the BiPACS trial
by trained study coordinators and investigators, with permission from
the attending surgeon. All patients in the study give written, informed
consent. Eligibility criteria include preoperative congestive heart fail-
ure, an LVEF of 40% or lower and a QRSd of 100 milliseconds or
greater, or combined mitral and aortic valve replacement. Patients are
excluded for atrial fibrillation, second- or third-degree AV block,
congenital heart disease, intracardiac shunts, or heart rate greater
than 120 bpm after CPB.Study Design and Protocol
All BiPACS patients undergo BiVP optimization during phases I, II, and
III, defined above. Randomization is done after phase I. In addition,
patients in the BiVP group are paced continuously between phases I and
III. The primary end point is cardiac index measured by thermodilution
in the ICU. The present study does not examine primary end point data.
In phase I, 38 settings of BiVPwith varying AVD, VVD, and ventricular
placing sites are tested in randomized order to determine an optimal BiVP
protocol designated P1, optimized with an aortic flow probe. P1 is tested
against AAI at the same heart rate and against the patient’s intrinsic sinus
rhythm at the end of phase I.
In phase II, BiVP settings are again tested in a different randomized
order to determine a second optimal BiVP protocol, P2. P1 and P2 are
then compared against each other and against AAI and no pacing, at the
end of phase II. Mean arterial pressure (MAP) is a surrogate marker for
CO in phase II, because chest closure precludes use of flow probes and
time constraints obviate use of thermodilution.
Patients in the BIVP group are paced from the end of phase I to the
start of phase II under protocol P1. The BIVP group is then paced
from phase II to phase III with the optimum phase II protocol (either
P1 or P2), as determined using MAP. Patients in the standard-of-care
(SOC) group are not paced between phases. The primary end point at
the start of phase III is CO by thermodilution, using a Swan-Ganz
catheter.
At the start of phase III, the active pacing protocol is again
compared with AAI and no pacing using thermodilution CO; 212 set-
tings of AVD and VVD are then tested in random order. The 10 settings
yielding the highest MAP are retested to determine an optimal phase III
setting, P3. P3 is finally compared with AAI and no pacing by thermo-
dilution CO.Data Analysis
At all phases, electrocardiographic and arterial pressure tracings are
recorded. In phase I, flow velocity is recorded using an aortic flow probe.
Data are converted to digital form with a PowerLab AD system (ADInstru-
ments, Inc, Colorado Springs, Colo) and stored on a personal computer
(Apple Computer, Inc, Cupertino, Calif) withMacLab software (ADInstru-
ments, Inc). Data are then loaded into Matlab (The MathWorks, Inc, Na-
tick, Mass), where heart rate, CO, and MAP are averaged and recorded
over one respiratory cycle toward the end of no pacing, AAI, and optimized
BiVP segments.17,18 Doses of vasoactive medications and duration of
sedative infusions are obtained from the Eclipsys patient record system
(Allscripts Healthcare Solutions, Inc, Chicago, Ill) at New York–
Presbyterian Hospital. Vasoactive-inotrope scores were calculated as
described in a prior substudy22:diovascular Surgery c Volume 146, Number 6 1495
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MVIS ¼ Dopamine Dose ðmg=kg per minuteÞ
þ Dobutamine Dose ðmg=kg per minuteÞ
þ 100 3 Epinephrine Dose ðmg=kg per minuteÞ
þ 10 3 Milrinone Dose ðmg=kg per minuteÞ
þ 10; 000 3 Vasopressin Dose ðU=kg per minuteÞ
þ 100 3 Norepinephrine Dose ðmg=kg per minuteÞ
þ 10 3 Phenylephrine Dose ðmg=kg per minuteÞ
These data were then evaluated for changes and differences in intrinsic
heart rate, CO, MAP, and drug administration times. To determine whether
there was an increasing or decreasing trend in heart rate between phases,
paired t-tests were conducted, with P< .05 considered significant. To
determine differences between BiVP and SOC groups, 2-sample t-tests
were conducted, with P < .05 again considered significant. Statistical
analysis was performed using SAS 9.1 (SAS Institute, Inc, Cary, NC).RESULTS
Study Population
Table 1 displays the average baseline characteristics
(mean  SD) of 34 patients examined in this substudy,
16 in the BiVP group and 18 in the SOC group.
There were no significant differences between the BiVP
and SOC groups in age (71  8 vs 68  11 years;
P ¼ .35), sex (males, 81% vs 78%; P ¼ .80), weight
(70  14 vs 78  15 kg; P ¼ .14), preoperative LVEF
(35.6%  12.8% vs 30.7%  16.4%; P ¼ .34). There
was also no significant difference between the groups in
the type of surgery based on the number of coronary artery
bypass grafts (c2 ¼ 6.39, P ¼ .17), or the number of aortic
valve replacements or repairs (c2 ¼ 2.24, P ¼ .13).
The BiVP group had more mitral valve replacements or
repairs compared with SOC patients (13/16 vs 7/18TABLE 1. Patient baseline characteristics
Characteristic
Randomized to
BiVP (n ¼ 16)
Randomized to
SOC (n ¼ 18)
P
value
Age, y 70.8  7.5 67.6  11.4 .35
Male sex,%* 81 78 .80
Weight, kg 70.1  14.4 77.7  14.9 .14
Preoperative LVEF,% 35.6  12.8 30.7  16.4 .34
Preoperative QRS, ms 116.5  21.2 120.1  23.1 .64
Bypass time, min 163.6  73.3 128.5  35.6 .08
Crossclamp time, min 102.8  53.1 81.6  39.5 .21
Type of surgery
CABG (0, 1, 2, 3, 4)*,y 7, 2, 3, 0, 3 6, 1, 2, 6, 3 .17
AVR/r (0, R, r)*,z 4, 12, 0 9, 9, 0 .13
MVR/r (0, R, r)*,x 3, 7, 6 11, 3, 4 .04
Data are given as mean SD unless otherwise indicated. BiVP, Biventricular pacing;
SOC, standard of care; LVEF, left ventricular ejection fraction; CABG, coronary
artery bypass grafting; AVR/r, aortic valve replacement/repair; MVR/r, mitral valve
replacement/repair; QRS, duration of QRS complex on electrocardiogram, in milli-
seconds. *Statistical significance calculated through c2 test. yShown as number of pa-
tients with 0, 1, 2, 3, 4 bypasses. zShown by number of patients with no repair,
replacement, or repair to the aortic valve. xShown by number of patients with no
repair, replacement, or repair to the mitral valve.
1496 The Journal of Thoracic and Cardiovascular Surpatients; c2 ¼ 6.48, P ¼ .04). There was a trend toward
increased duration of CPB in the BiVP group (164  73
vs 128  36 minutes; P ¼ .08), but no significant differ-
ences in crossclamp time (103  53 vs 82  40 minutes;
P ¼ .21).Clinical Results
Figure 1 presents average intrinsic heart rates at the end
of phases I and II and the beginning of phase III. These
data were obtained during comparisons between BiVP,
AAI, and no pacing. Compared with SOC patients, heart
rate was significantly lower in BiVP patients in phase III
(76.5 17.5 vs 91.7 13.0 bpm; P¼ .040), but not signifi-
cantly different in phase I (77.2 19.7 vs 78.3 14.7 bpm;
P ¼ .87) and phase II (83.1  14.1 vs 86.0  18.7 bpm;
P ¼ .67). There was a trend toward decreasing intrinsic
heart rate from phase II to phase III in the BiVP group
(76.5  17.5 vs 86.0  18.7 bpm; P ¼ .063), but not in
SOC patients (83.1  14.1 vs 91.7  13.0 bpm; P ¼ .45).
Table 2 presents average hemodynamics for all patients
studied. From phase I to phase III, there was an upward
trend in BiVP patients of CO (4.4  1.2 vs 3.6  1.9 L/
min; P ¼ .054) and stroke volume (53.4  17.3 vs 42.5 
21.4 mL; P ¼ .051) (Figure 2). There was no significant
change in MAP in the BiVP group from phase I to phase
II (76.4  9.5 vs 74.6  12.2 mm Hg; P ¼ .76), or phase
II to phase III (74.6  12.2 vs 79.9  12.8 mm Hg;
P ¼ .15). In the SOC group, there was no significant
increase in CO (5.1  1.1 vs 4.8  1.3 L/min; P ¼ .14)
or stroke volume (55.9  14.1 vs 55.5  14.7 mL;
P¼ .95) between phases I and III. There were no significant
changes in MAP for SOC patients from phase I to phase II
(69.9  8.7 vs 74.5  11.5 mm Hg; P ¼ .16) andFIGURE 1. Mean intrinsic heart rates for biventricular pacing (BiVP)
(n¼ 16) and standard-of-care (SOC) (n¼ 18) groups from phase I to phase
III. Brackets indicate P values. Intrinsic heart rate in the BiVP group was
significantly lower than in the SOC group in phase III. A trend of
decreasing heart rates in BiVP patients from phase II to phase III is not sta-
tistically significant (P ¼ .0631). Data from Table 2.
gery c December 2013
TABLE 2. Hemodynamics of BiPACS patients in phases I to III
Settings





L/min SV, mL HR MAP HR MAP CO SV
No. of
patients 16 12 12 12 12 10 10 13 13 13 13
BiVP
(n ¼ 16)
NoP 77.2  19.7 76.4  9.5 3.56  1.85 42.5  21.4 86.0  18.7 74.6  12.2 76.5  17.5 79.9  12.8 4.40  1.17 53.4  17.3
AAI 96.5  11.0 79.3  9.4 3.65  1.82 37.4  18.1 98.0  12.0 75.7  11.9 94.8  13.0 88.3  12.6 4.89  1.19 50.6  14.4
BiVP 96.3  10.6 79.9  12.0 4.08  2.19 42.7  22.9 95.8  11.0 78.8  13.4 94.8  13.0 85.6  12.5 4.86  1.54 49.1  14.5
No. of
patients 18 18 18 18 18 14 14 9 9 9 9
SOC
(n ¼ 18)
NoP 78.3  14.7 69.9  8.7 4.79  1.33 55.9  14.1 83.1  19.1 74.5  11.5 91.7  13.0 74.5  11.0 5.05  1.11 55.5  14.7
AAI 92.3  10.1 71.8  11.0 4.54  1.56 49.2  17.2 96.1  11.0 75.9  13.1 98.5  8.4 81.4  11.2 5.45  1.17 56.2  13.4
BiVP 95.8  7.4 76.4  14.1 5.17  1.60 54.8  18.7 97.0  9.2 77.4  10.1 100.2  9.5 82.2  10.9 5.14  1.12 51.4  13.1
All
(N ¼ 34)
NoP 77.9  16.6 72.5  9.4 4.31  1.64 48.8  19.1 84.3  15.9 74.6  11.5 82.7  17.3 77.9  12.1 4.69  1.17 54.4  15.6
AAI 94.2  10.5 75.1  10.8 4.15  1.70 44.0  18.2 96.9  11.2 75.1  12.3 96.3  11.3 85.5  12.3 5.13  1.19 52.9  14.0
BiVP 96.0  8.8 78.0  13.2 4.68  1.94 49.4  21.2 96.5  9.8 77.8  11.5 97.2  11.7 84.1  11.7 4.98  1.35 50.1  13.7
Data are given as mean  SD. BiPACS, Biventricular Pacing after Cardiac Surgery; HR, heart rate; bpm, beats per minute; MAP, mean arterial pressure; CO, cardiac output;
SV, stroke volume; BiVP, biventricular pacing; NoP, no pacing; AAI, atrial pacing; SOC, standard of care.
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Mphase II to phase III (74.5  11.5 vs 75.0  11.0 mm Hg;
P ¼ .93).
Figure 3 presents the relation of percentage changes in
heart rate and CO during AAI pacing in phase III. There
is a significant relationship between these variables for
both the BiVP patients (P ¼ .002) and all patients
(P ¼ .005), in which percentage change in heart rate is
roughly twice the percentage change in CO.
Figure 4 and Table 3 present the average vasoactive-
inotrope score (VIS) of both BiVP and SOC patients at all
3 phases. VIS trended lower in BiVP than SOC patients
in phase I (10.9  8.0 vs 13.3  10.9; P ¼ .502),FIGURE 2. Mean stroke volume (SV) without pacing for biventricular
pacing (BiVP) and standard-of-care (SOC) groups at phase I and phase
III. Trend toward increasing SV in the BiVP group (P ¼ .051). Data
from Table 2.
The Journal of Thoracic and Carphase II (9.5  6.7 vs 13.2  10.8; P ¼ .277), and phase
III (7.5  7.4 vs 8.4  9.2; P ¼ .776), although differences
were not statistically significant.
Figure 5 presents drug administration time for propofol,
dexmedetomidine, and fentanyl in the ICU. Dexmedetomi-
dine administration was prolonged in BiVP patients (793
528 vs 478  295 minutes; P ¼ .013). There was no signi-
ficant difference in propofol (497  328 vs 394  331
minutes; P ¼ .270) or fentanyl (802  545 vs 547  352
minutes; P ¼ .242) duration. There was no significant
difference in duration of ventilation between the groups
(1.37  1.05 vs 1.34  1.72 days; P ¼ .94).FIGURE 3. Percentage change in heart rate (HR) and cardiac output (CO)
during atrial pacing (AAI) at phase III. Regression lines are for all patients
(n ¼ 21), and biventricular pacing (BiVP) patients only (n ¼ 13) indicate
the percentage change in HR is roughly twice the percentage change in
CO. SOC, Standard of care.
diovascular Surgery c Volume 146, Number 6 1497
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TABLE 3. Administration of vasoactive medications in phases I, II,
and III
Phase I Phase II Phase III
BiVP (n ¼ 16) 10.9  8.0 9.7  6.7 7.5  7.4
SOC (n ¼ 18) 13.3  10.9 13.2  10.8 8.4  9.2
BiVP, Biventricular pacing; SOC, standard of care.
FIGURE 4. Meanvasoactive-inotrope score (VIS) for biventricular pacing
(BiVP) and standard-of-care (SOC) groups. No difference in VISwas found
in phases I, II, and III.
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MDISCUSSION
This substudy examines why AAI pacing becomes more
effective over 12 to 24 hours after CPB relative to BiVP.17,18
One possibility is that decreasing intrinsic heart rates makes
pacing-induced heart rate increases proportionately more
important over time. Because the design of the BiPACS
trial was based, in part, on the assumption that intrinsic
heart rate would be similar in both study arms, this
assumption requires confirmation.
In fact, we find a significantly lower intrinsic heart rate at
phase III in the BiVP group, a difference not present in
phases I and II. Furthermore, heart rate trended downward
in BiVP patients from chest closure to 12 to 24 hours
postoperatively.
Intrinsic heart rate in postoperative patients is affected by
factors that are broadly divided into extrinsic stimuli,
medication effects, and intrinsic autonomic effects.
Extrinsic stimuli, such as pain, discomfort, and bedside
activities, can increase arousal and intrinsic heart rate.20FIGURE 5. Mean administration time of propofol, dexmedetomidine,
and fentanyl for biventricular pacing (BiVP) and standard-of-care
(SOC) groups. BiVP patients were administered dexmedetomidine for
significantly longer than SOC patients.
1498 The Journal of Thoracic and Cardiovascular SurMedications include positive chronotropes, such as sympa-
thomimetic amines and sedatives, which exert a negative
chronotropic effect.21-23 Intrinsic autonomic effects are
vagal or sympathetic, and can be affected by anxiety or
feedback loops related to blood pressure, lactate levels,
and atrial volume receptors.24
There are 3 potential explanations for the decreasing
postoperative intrinsic heart rate observed in this study.
First, improved hemodynamics during BiVP can reduce
internal sympathetic drive. Trends in the BiVP group
toward increasing CO and stroke volume from phase I to
III are consistent with this concept and could reflect
accelerated recovery from ischemia-reperfusion injury by
BiVP. CO and stroke volume increase approximately
25% from phase I to phase III. Although BiVP can increase
CO 15% to 20% compared with other forms of pacing,13
persistence of increased CO when pacing is turned off is
more consistent with myocardial recovery than acute
mechanical effects of pacing. Analysis of the primary end
point of the BiPACS has addressed the overall effect of
the pacing protocol.25
A second, related possibility is that reduced vasopressor
and inotrope requirements decrease intrinsic heart rate in
the BiVP group. A previous substudy from the BiPACS trial
demonstrated reduced VIS in BiVP patients over 3 hours
after CPB.19 How hemodynamics would influence the
administration of vasoactive agents is undefined, however,
and administration of these drugs is not regulated by
protocol at Columbia.19 The present analysis demonstrates
no significant difference in VIS between BiVP and SOC
patients in phase III. Heart rate differences in phase III,
therefore, probably do not reflect differences in vasoactive
medication doses, although a small trend to decreased
VIS in the BiVP group is present.
A third factor may be higher doses of sedatives in BiVP
patients.22,23 In fact, BiVP patients did receive
dexmedetomidine for longer periods. Because there was
little difference between groups in ventilation time, the
reason for prolonged administration of dexmedetomidine
in BiVP patients remains unexplained.
Stroke volume was significantly lower (P ¼ .020) in
BiVP than SOC patients at phase I, indicating that the
randomized groups were not precisely equivalent. In fact,
mitral valve repair was more frequent in the BiVP group
(P ¼ .04) and bypass time trended to be longer (P ¼ .08).
Despite these differences, stroke volume increased signifi-
cantly between phases I and III only in the BiVP groupgery c December 2013
Lu et al Perioperative Management
P
M(P ¼ .051), suggesting clinical benefit. At phase III, there
was no statistical difference between the BiVP and SOC
groups in stroke volume (P ¼ .344).
Taken together, these factors are all likely to contribute to
the lower heart rate observed in BiVP patients in the ICU.
Lower intrinsic heart rate in BiVP patients may reflect
reduced infusion of agents with chronotropic effects.
This, in turn, could decrease frequency of atrial and
ventricular arrhythmias and decrease requirements for
antiarrhythmics.26
Our results support the view that lower heart rates
augment the fractional increase in rate associated with
pacing in the BiPACS trial. For BiVP patients, an average
heart rate increase of 24% from 76.5 to 94.8 bpm during
AAI pacing is accompanied by an 11% increase in cardiac
output from 4.4 to 4.9 L/min (Table 2). This change matches
the slope of the regressions in Figure 3. Therefore, the
increased benefit of AAI pacing at phase III can be ex-
plained by decreased intrinsic heart rates. This observation
applies only to the BiVP group. Similar effects are not seen
in phase I, where increasing heart rate is associated with
decreased stroke volume, and only BiVP pacing can
augment cardiac output.
Limitations
The study is limited by missing data. For the 16 BiVP
patients, heart rate data were available for 12 in phase
I, 10 in phase II, and 13 in phase III. For the 18 SOC pa-
tients, heart rate data were available for 18 in phase I, 14
in phase II, and 9 in phase III. Thus, exclusion bias could
confound the present results. Causes of missing data include
heart block, which precluded measurement of intrinsic rate.
A clinical difference between randomization groups was
a higher rate of mitral valve replacements and repairs in the
BiVP group versus the SOC group. There were also trends
toward longer bypass and crossclamp times for the BiVP
group (Table 1). These trends were not associated with
differences in intrinsic heart rate between groups in phases
I and II (Figure 1). Stroke volumewas significantly lower in
BiVP than SOC patients at phase I. However, by phase III,
there was no statistical difference in stroke volume between
BiVP and SOC, suggesting a clinical benefit in the BiVP
group leading to equalization between groups.
CONCLUSIONS
BiVP-randomized patients had lower intrinsic heart
rates 12 to 24 hours after CPB compared with patients
randomized to standard of care. This difference is further
underscored by the observation that BiVP patients had a
decreasing trend of intrinsic heart rates from immediately
after chest closure to the ICU. These findings could be ex-
plained by a beneficial effect of optimized BiVP, as
evidenced by increasing trends of cardiac output and stroke
volume from after bypass to the ICU. However, the role ofThe Journal of Thoracic and Carmedications, such as vasopressors and inotropes, and heart
rate–lowering medications, such as dexmedetomidine,
needs to be further elucidated. Depression of intrinsic
heart rate may contribute to increased benefit of heart rate
acceleration by pacing in this clinical trial.References
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